Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.
Francesco SaladiniAlessia GianniniAdele BoccutoIlaria VicentiMaurizio ZazziPublished in: Journal of clinical laboratory analysis (2017)
The described phenotypic assay can be adopted to evaluate the antiviral activity of licensed and investigational HIV-1 drugs targeting any of the three HIV-1 enzymes.